Tyk Medicines Inc. (2410)
Market Closed
12 Dec, 08:00
HKEX HKEX Primary 13. 32
HKD +0.45
+3.5%
7.6B Market Cap
- P/E Ratio
0% Div Yield
3,471,507 Volume
- Eps
12.87 HKD
Previous Close Day Range
12.9 13.6
Year Range
12.1 56.55
Want to track 2410 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
2410 closed Friday higher at 13.32 HKD, an increase of 3.5% from Thursday's close, completing a monthly decrease of -4.86% or 0.68 HKD. Over the past 12 months, 2410 stock lost -73.09%.
2410 is not paying dividends to its shareholders.
The stock of the company had never split.
The company's stock is traded on 1 different exchanges and in various currencies, with the primary listing on HKEX (HKD).
Tyk Medicines Inc. (2410) FAQ
What is the stock price today?
The current price is 13.32 HKD.
On which exchange is it traded?
Tyk Medicines Inc. is listed on HKEX.
What is its stock symbol?
The ticker symbol is 2410.
Does it pay dividends? What is the current yield?
Yes, It pays dividends and the current yield is 0%.
What is its market cap?
As of today, the market cap is 7.6B.
Has Tyk Medicines Inc. ever had a stock split?
No, there has never been a stock split.
Tyk Medicines Inc. Profile
| Biotechnology Industry | Healthcare Sector | Dr. Yusheng Wu CEO | HKEX Exchange | - ISIN |
| China Country | - Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
TYK Medicines, Inc. is a clinical-stage biopharmaceutical company dedicated to pioneering the research, acquisition, development, and commercialization of innovative treatments aimed at fulfilling the void in cancer care. Since its inception in 2017, TYK Medicines has carved a niche for itself within the pharmaceutical industry with its headquarters based in Huzhou, China. The company's strategic focus on harnessing cutting-edge science to develop therapies for unmet medical needs in cancer treatment positions it as a key player in the global battle against cancer.
Products and Services
- TY-9591: A third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor designed for the treatment of brain metastases from non-small cell lung cancer (NSCLC) with EGFR mutations, and in locally advanced or metastatic NSCLC with EGFR L858R mutation.
- TY-302: An oral cyclin-dependent kinase (CDK) 4/6 inhibitor under development to treat solid tumors, including breast cancer and prostate cancer.
- TY-2136b: An oral ROS proto-oncogene 1/neurotrophic tyrosine receptor kinase inhibitor aimed at treating solid tumors.
- TY-2699a: A selective CDK7 inhibitor in development for the treatment of advanced/metastatic solid tumors.
- TY-0540: A selective CDK2/4/6 inhibitor targeting the treatment of advanced/metastatic solid tumors.
- TY-4028: An oral exon 20 insertion-TKI (tyrosine kinase inhibitor) focused on treating locally advanced or metastatic NSCLC with EGFR exon 20 or HER2 exon 20 insertions.
- TY-1091: A potent and selective rearranged during transfection proto-oncogene (RET) inhibitor for treating advanced NSCLC with RET gene fusion, advanced medullary thyroid cancer with RET gene mutation, and other advanced solid tumors with RET gene alterations.
- TY-1054: An oral yes associated protein-transcriptional enhanced associate domain inhibitor for cancer treatment.
- TY-1210: A selective CDK2 inhibitor under development for treating solid tumors.
- TY-0609: A selective CDK4 inhibitor in the pipeline for cancer treatment.
- TY-3200: An EGFR degrader being developed to address advanced metastatic solid tumors.
Contact Information
Address: Tower A, Changxing World Trade Building
Phone: 86 21 6167 6766
Website: https://www.tykmedicines.com
2025 © Marketlog. All Rights Reserved.
